NCT01191697 2025-11-03
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
15 trialsNCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04164069 2024-12-27
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00911820 2022-11-08
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01212822 2022-09-07
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00393068 2022-03-02
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed
NCT00217581 2019-03-26
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00137813 2018-11-01
Avastin and Taxotere for Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00394433 2017-08-01
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00354679 2016-05-16
Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed